Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Core Viewpoint - Phathom Pharmaceuticals, Inc. will host a live webcast on August 7, 2025, to report its second quarter 2025 financial results and provide a business update [1]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3]. - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) [3]. - Vonoprazan is marketed in the U.S. as VOQUEZNA for various gastrointestinal conditions, including heartburn relief associated with Non-Erosive GERD and treatment of H. pylori infection [3].